Blueshift Asset Management LLC Buys 1,601 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Blueshift Asset Management LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 99.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 3,217 shares of the medical research company’s stock after acquiring an additional 1,601 shares during the period. Blueshift Asset Management LLC’s holdings in IQVIA were worth $567,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after buying an additional 854,732 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after buying an additional 712,958 shares during the period. D. E. Shaw & Co. Inc. increased its stake in shares of IQVIA by 211.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company’s stock worth $189,691,000 after acquiring an additional 655,153 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in IQVIA by 85.4% during the 4th quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company’s stock valued at $187,528,000 after acquiring an additional 439,649 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of IQV stock opened at $182.44 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $31.01 billion, a P/E ratio of 26.40, a P/E/G ratio of 2.04 and a beta of 1.30. The company’s 50-day simple moving average is $162.11 and its two-hundred day simple moving average is $170.07. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.64 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. Citigroup reiterated a “neutral” rating on shares of IQVIA in a report on Thursday, May 22nd. HSBC downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Truist Financial lifted their price target on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Evercore ISI increased their price objective on shares of IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday, July 9th. Finally, Robert W. Baird increased their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.